Logo image
Back
Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis
Journal article   Open access   Peer reviewed

Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis

G.L. Maker, B. Siva, K.T Batty, R.D. Trengove, P. Ferrari and J.K. Olynyk
Nephrology, Vol.18(3), pp.188-193
2013
DOI: https://doi.org/10.1111/nep.12035
pdf
pharmacokinetics_and_safety_of_deferasirox.pdfDownloadView
Author’s Version Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Aim Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is one of the most promising. However, it has not been studied in patients with CKD and iron overload. Methods A pilot study was conducted to evaluate the pharmacokinetics and safety of deferasirox in eight haemodialysis-dependent patients, who were receiving intravenous iron for treatment of anaemia of CKD. Deferasirox was administered at two doses (10 mg/kg and 15 mg/kg), either acute (once daily for 2 days) or steady-state (once daily for 2 weeks). Results A dose of 10 mg/kg in either protocol was not sufficient to achieve a plasma concentration in the therapeutic range (acute peak 14.1 and steady-state 22.8 μmol/L), while 15 mg/kg in either protocol maintained plasma concentration well above this range (acute peak 216 and steady-state 171 μmol/L). Plasma concentration observed at 15 mg/kg was well above that expected for this dose (40-50 μmol/L), although no adverse clinical events were observed. Conclusion This study highlights the need to profile drugs such as deferasirox in specific patient groups, such as those with CKD and iron overload. The authors examined the acute and steady-state pharmacokinetics of two-dose protocol of deferasirox in patients undergoing haemodialysis. The study revealed the importance of individual dose profile as the dose response varies in patients with CKD with iron overload.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

319 File views/ downloads
109 Record Views
16 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.184 Physiology & Metals
1.184.573 Iron Metabolism
Web Of Science research areas
Urology & Nephrology
ESI research areas
Clinical Medicine
Logo image